Synopsis
Synopsis
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 5 Formyltetrahydrofolate
2. 5 Formyltetrahydropteroylglutamate
3. 5-formyltetrahydrofolate
4. 5-formyltetrahydropteroylglutamate
5. Acid, Folinic
6. Calcium Folinate
7. Citrovorum Factor
8. Factor, Citrovorum
9. Folinate, Calcium
10. Folinic Acid
11. Folinic Acid Sf
12. Folinic Acid-sf
13. Leucovorin
14. Leucovorin, (d)-isomer
15. Leucovorin, (dl)-isomer
16. Leucovorin, (r)-isomer
17. Leucovorin, Calcium
18. Leucovorin, Calcium (1:1) Salt
19. Leucovorin, Calcium (1:1) Salt, (dl)-isomer
20. Leucovorin, Calcium (1:1) Salt, Pentahydrate
21. Leucovorin, Monosodium Salt
22. Leukovorin
23. Leukovorum
24. Monosodium Salt Leucovorin
25. N(5)-formyltetrahydrofolate
26. Wellcovorin
1. Calcium Folinate
2. Calcium Citrovorum Factor
3. Folinic Acid Calcium Salt
4. Folinic Acid-sf, Calcium Salt
5. (+)-l-folinic Acid, Calcium Salt
6. 1492-18-8
7. Nsc3590
8. Sr-05000001662
9. Pharmakon1600-01500364
10. Nsc757083
11. Nsc-757083
12. Sr-05000001662-1
13. Sr-05000001662-2
14. Glutamic Acid,6,7,8-tetrahydro-4-hydroxy-6- Pteridinyl)methyl]amino]benzoyl]-, Calcium Salt (1:1), L-
15. L-glutamic Acid,4,5,6,7,8-hexahydro-4-oxo-6- Pteridinyl)methyl]amino]benzoyl]-, Calcium Salt (1:1), (s)-
| Molecular Weight | 513.5 g/mol |
|---|---|
| Molecular Formula | C20H23CaN7O7+2 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 9 |
| Exact Mass | 513.1284869 g/mol |
| Monoisotopic Mass | 513.1284869 g/mol |
| Topological Polar Surface Area | 216 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 2 |
| Complexity | 911 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Antidotes
Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)
Vitamin B Complex
A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AF - Detoxifying agents for antineoplastic treatment
V03AF03 - Calcium folinate
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Panvo Organics: Advancing quality APIs and formulations with Halal, Kosher, US FDA, and WHO-approved manufacturing excellence.
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-08-16
Pay. Date : 2019-06-24
DMF Number : 33740
Submission : 2019-05-18
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2018-03-02
Pay. Date : 2018-02-20
DMF Number : 5261
Submission : 1984-01-23
Status : Active
Type : II
Certificate Number : R1-CEP 1996-055 - Rev 08
Issue Date : 2023-05-19
Type : Chemical
Substance Number : 978
Status : Valid
Registration Number : 218MF10352
Registrant's Address : Weisshausmatte, 6460 Altdorf UR, Switzerland
Initial Date of Registration : 2006-03-17
Latest Date of Registration :
Registrant Name : Wooshin Labotach Co., Ltd.
Registration Date : 2021-04-05
Registration Number : 20210405-210-J-686
Manufacturer Name : Merck & Cie KmG@Dottikon Exclusive Synthesis AG
Manufacturer Address : Im Laternenacker 5,CH-8200 Schaffhausen, Switzerland@Hembrunnstrasse 17 CH-5605 Dottikon Switzerland

GDUFA
DMF Review : Reviewed
Rev. Date : 2024-07-26
Pay. Date : 2024-06-10
DMF Number : 38878
Submission : 2023-09-27
Status : Active
Type : II
Certificate Number : R1-CEP 2011-370 - Rev 00
Issue Date : 2019-07-26
Type : Chemical
Substance Number : 978
Status : Valid

GDUFA
DMF Review : Reviewed
Rev. Date : 2024-10-18
Pay. Date : 2024-09-19
DMF Number : 40427
Submission : 2024-09-04
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16718
Submission : 2003-07-18
Status : Inactive
Type : II
Certificate Number : CEP 2004-009 - Rev 04
Issue Date : 2024-04-15
Type : Chemical
Substance Number : 978
Status : Valid
Registration Number : 227MF10147
Registrant's Address : 6, rue des Iles CH-2108 COUVET Switzerland
Initial Date of Registration : 2015-05-20
Latest Date of Registration :

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25334
Submission : 2011-08-09
Status : Inactive
Type : II

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3715
Submission : 1980-02-11
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25334
Submission : 2011-08-09
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2019-08-16
Pay. Date : 2019-06-24
DMF Number : 33740
Submission : 2019-05-18
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16718
Submission : 2003-07-18
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2024-07-26
Pay. Date : 2024-06-10
DMF Number : 38878
Submission : 2023-09-27
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2018-03-02
Pay. Date : 2018-02-20
DMF Number : 5261
Submission : 1984-01-23
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2024-10-18
Pay. Date : 2024-09-19
DMF Number : 40427
Submission : 2024-09-04
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3715
Submission : 1980-02-11
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10232
Submission : 1993-03-06
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5429
Submission : 1984-07-09
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
Aflibercept is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Lead Product(s): Aflibercept,Fluorouracil,Calcium Folinate,Irinotecan Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: CR-CSSS Champlain-Charles-Le Moyne
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2014
Lead Product(s) : Aflibercept,Fluorouracil,Calcium Folinate,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : CR-CSSS Champlain-Charles-Le Moyne
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aflibercept is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 24, 2014
Details:
Aflibercept is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): Aflibercept,Calcium Folinate,Irinotecan Hydrochloride,Fluorouracil
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Regeneron Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2013
Lead Product(s) : Aflibercept,Calcium Folinate,Irinotecan Hydrochloride,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aflibercept is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 29, 2013
Details:
Sarilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uveitis.
Lead Product(s): Sarilumab,Prednisone,Methotrexate,Calcium Folinate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 16, 2013
Lead Product(s) : Sarilumab,Prednisone,Methotrexate,Calcium Folinate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
Details : Sarilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uveitis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 16, 2013
Details:
Aflibercept is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Lead Product(s): Aflibercept,Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Regeneron Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2012
Lead Product(s) : Aflibercept,Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aflibercept is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 22, 2012
Details:
Aflibercept is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colonic Neoplasms.
Lead Product(s): Aflibercept,Oxaliplatin,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: John Hays
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 27, 2012
Lead Product(s) : Aflibercept,Oxaliplatin,Calcium Folinate,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : John Hays
Deal Size : Inapplicable
Deal Type : Inapplicable
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Details : Aflibercept is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colonic Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 27, 2012
Details:
Aflibercept is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Lead Product(s): Aflibercept,Calcium Folinate,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Regeneron Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 05, 2012
Lead Product(s) : Aflibercept,Calcium Folinate,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aflibercept is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 05, 2012
Details:
Sarilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthritis, Rheumatoid.
Lead Product(s): Sarilumab,Methotrexate,Calcium Folinate
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Regeneron Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 08, 2010
Lead Product(s) : Sarilumab,Methotrexate,Calcium Folinate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sarilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 08, 2010
Details:
Leucovorin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pancreatic Neoplasms.
Lead Product(s): Calcium Folinate,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 12, 2010
Lead Product(s) : Calcium Folinate,Oxaliplatin,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
Details : Leucovorin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2010
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Telisotuzumab Adizutecan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Lead Product(s): Telisotuzumab Adizutecan,Fluorouracil,Calcium Folinate,Oxaliplatin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 24, 2026
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telisotuzumab Adizutecan,Fluorouracil,Calcium Folinate,Oxaliplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Telisotuzumab Adizutecan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
March 24, 2026
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Telisotuzumab Adizutecan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Lead Product(s): Telisotuzumab Adizutecan,Fluorouracil,Oxaliplatin,Calcium Folinate,Bevacizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 11, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Telisotuzumab Adizutecan,Fluorouracil,Oxaliplatin,Calcium Folinate,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Telisotuzumab Adizutecan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
February 11, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.
Regulatory Info :
Registration Country : France
Brand Name :
Dosage Form : Vial
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 50MG
Brand Name :
Approval Date :
Application Number :
Registration Country : France
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.
Regulatory Info :
Registration Country : France
Brand Name :
Dosage Form : Vial
Dosage Strength : 350MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 350MG
Brand Name :
Approval Date :
Application Number :
Registration Country : France
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 50MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 100MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 200MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 350MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 350MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 50MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 100MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 200MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
16 Apr 2026
Reply
04 Oct 2025
Reply
13 Sep 2025
Reply
03 May 2025
Reply
11 Feb 2025
Reply
31 Jan 2025
Reply
23 Jan 2025
Reply
09 Sep 2024
Reply
03 Sep 2024
Reply
26 Jan 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
41
PharmaCompass offers a list of Calcium Folinate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Calcium Folinate manufacturer or Calcium Folinate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Calcium Folinate manufacturer or Calcium Folinate supplier.
A Leucovorin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Leucovorin, including repackagers and relabelers. The FDA regulates Leucovorin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Leucovorin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Leucovorin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Leucovorin supplier is an individual or a company that provides Leucovorin active pharmaceutical ingredient (API) or Leucovorin finished formulations upon request. The Leucovorin suppliers may include Leucovorin API manufacturers, exporters, distributors and traders.
click here to find a list of Leucovorin suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Leucovorin DMF (Drug Master File) is a document detailing the whole manufacturing process of Leucovorin active pharmaceutical ingredient (API) in detail. Different forms of Leucovorin DMFs exist exist since differing nations have different regulations, such as Leucovorin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Leucovorin DMF submitted to regulatory agencies in the US is known as a USDMF. Leucovorin USDMF includes data on Leucovorin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Leucovorin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Leucovorin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Leucovorin Drug Master File in Japan (Leucovorin JDMF) empowers Leucovorin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Leucovorin JDMF during the approval evaluation for pharmaceutical products. At the time of Leucovorin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Leucovorin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Leucovorin Drug Master File in Korea (Leucovorin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Leucovorin. The MFDS reviews the Leucovorin KDMF as part of the drug registration process and uses the information provided in the Leucovorin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Leucovorin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Leucovorin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Leucovorin suppliers with KDMF on PharmaCompass.
A Leucovorin CEP of the European Pharmacopoeia monograph is often referred to as a Leucovorin Certificate of Suitability (COS). The purpose of a Leucovorin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Leucovorin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Leucovorin to their clients by showing that a Leucovorin CEP has been issued for it. The manufacturer submits a Leucovorin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Leucovorin CEP holder for the record. Additionally, the data presented in the Leucovorin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Leucovorin DMF.
A Leucovorin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Leucovorin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Leucovorin suppliers with CEP (COS) on PharmaCompass.
A Leucovorin written confirmation (Leucovorin WC) is an official document issued by a regulatory agency to a Leucovorin manufacturer, verifying that the manufacturing facility of a Leucovorin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Leucovorin APIs or Leucovorin finished pharmaceutical products to another nation, regulatory agencies frequently require a Leucovorin WC (written confirmation) as part of the regulatory process.
click here to find a list of Leucovorin suppliers with Written Confirmation (WC) on PharmaCompass.
Leucovorin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Leucovorin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Leucovorin GMP manufacturer or Leucovorin GMP API supplier for your needs.
A Leucovorin CoA (Certificate of Analysis) is a formal document that attests to Leucovorin's compliance with Leucovorin specifications and serves as a tool for batch-level quality control.
Leucovorin CoA mostly includes findings from lab analyses of a specific batch. For each Leucovorin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Leucovorin may be tested according to a variety of international standards, such as European Pharmacopoeia (Leucovorin EP), Leucovorin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Leucovorin USP).